EMEA-002463-PIP01-18
Key facts
| Active substance |
dostarlimab
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0303/2019
|
| PIP number |
EMEA-002463-PIP01-18
|
| Pharmaceutical form(s) |
Solution for infusion
|
| Condition(s) / indication(s) |
Treatment of all conditions contained in the category of malignant neoplasms (except haematopoietic and lymphoid tissue)
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
GlaxoSmithKline (Ireland) Limited
Tel.: +44 2089903836 |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|